Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

BioScience Health Innovations (BHIC) EBIT (2020 - 2025)

BioScience Health Innovations (BHIC) has disclosed EBIT for 6 consecutive years, with -$156669.0 as the latest value for Q4 2025.

  • Quarterly EBIT fell 1673.46% to -$156669.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $719051.0 through Dec 2025, up 726.5% year-over-year, with the annual reading at $719051.0 for FY2025, 726.5% up from the prior year.
  • EBIT for Q4 2025 was -$156669.0 at BioScience Health Innovations, down from -$8782.0 in the prior quarter.
  • The five-year high for EBIT was $457704.0 in Q2 2025, with the low at -$156669.0 in Q4 2025.
  • Average EBIT over 5 years is $20684.0, with a median of -$13378.5 recorded in 2021.
  • Peak annual rise in EBIT hit 899.53% in 2025, while the deepest fall reached 1673.46% in 2025.
  • Over 5 years, EBIT stood at -$14089.0 in 2021, then plummeted by 105.25% to -$28917.0 in 2022, then tumbled by 32.71% to -$38376.0 in 2023, then soared by 125.95% to $9957.0 in 2024, then tumbled by 1673.46% to -$156669.0 in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$156669.0, -$8782.0, and $457704.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.